Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C35H47N5O6 |
| Molecular Weight | 633.7776 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(C[C@@H](OC(=O)N2CCC(CC2)N3CCC4=C(NC3=O)C=CC=C4)C(=O)N5CCC(CC5)N6CCOCC6)=CC(C)=C1O
InChI
InChIKey=HTLWMOKBJQKDIJ-WJOKGBTCSA-N
InChI=1S/C35H47N5O6/c1-24-21-26(22-25(2)32(24)41)23-31(33(42)38-12-8-28(9-13-38)37-17-19-45-20-18-37)46-35(44)39-14-10-29(11-15-39)40-16-7-27-5-3-4-6-30(27)36-34(40)43/h3-6,21-22,28-29,31,41H,7-20,23H2,1-2H3,(H,36,43)/t31-/m1/s1
| Molecular Formula | C35H47N5O6 |
| Molecular Weight | 633.7776 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. | 2010 Jul |
|
| New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. | 2012 Feb |
|
| Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. | 2015 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:58 GMT 2023
by
admin
on
Sat Dec 16 11:18:58 GMT 2023
|
| Record UNII |
7L3WOA232W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
866086-05-7
Created by
admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
|
PRIMARY | |||
|
23654987
Created by
admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
|
PRIMARY | |||
|
BI-44370
Created by
admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
|
PRIMARY | Official Title: A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe IntensityPurpose: The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator. | ||
|
7L3WOA232W
Created by
admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
RESULTS: The primary endpoint, pain-free after two hours, was reached by significantly more subjects in the BI44370TA 400mg (20/73=27.4%) and eletriptan 40mg (24/69=34.8%) groups compared to placebo (6/70=8.6%, p=.0016), but not by subjects in the BI 44370 TA 200mg group (14/65=21.5%). The effect of 50mg BI44370TA (5/64=7.8%) was similar to that of placebo. Analysis of secondary endpoints supported the conclusion from the primary analysis. The frequency of adverse events was low in all groups.
CONCLUSION: Efficacy of BI 44370 TA was shown in a dose-dependent manner in the treatment of acute migraine attacks.
|
||
|
ACTIVE MOIETY |
Originator: Boehringer Ingelheim; Class: Antimigraine; Mechanism of Action: Calcitonin gene-related peptide receptor antagonist; Highest Development Phase: Discontinued for Migraine
|
